Scientific Advisory Board
Dr. Kristi Anseth, Howard Hughes Medical Investigator at the University of Colorado in Boulder
Kristi Anseth is a Tisone Distinguished Professor of Chemical and Biological Engineering at University of Colorado, Boulder. She is the first engineer selected as a Howard Hughes Medical Investigator. Dr. Anseth designs synthetic hydrogel biomaterials to imitate the extracellular matrix surrounding cells. Her pioneering approach is to apply photopolymerization and photodegradation to enable precise control in space and time over hydrogels' structure and composition, enabling fundamental investigations into the molecular dynamics of processes at the cell-biomaterial interface.
Dr. Anseth has been named by MIT Technology Review as one of the top 100 innovators in the world and elected onto the National Academy of Engineering, National Academy of Sciences, and National Academy of Inventors. She obtained her Ph.D. in Chemical Engineering at the University of Colorado, Boulder in 1994.
Dr. Anseth has been named by MIT Technology Review as one of the top 100 innovators in the world and elected onto the National Academy of Engineering, National Academy of Sciences, and National Academy of Inventors. She obtained her Ph.D. in Chemical Engineering at the University of Colorado, Boulder in 1994.
Dr. Ross M. Kedl, Faculty Professor, University of Colorado Denver School of Medicine
Dr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology.
Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer. Dr. Kedl's extensive experience with vaccine development and industry operations will greatly help Nanoly in its goal to eliminate the need for refrigeration of vaccines and therapeutics.
Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer. Dr. Kedl's extensive experience with vaccine development and industry operations will greatly help Nanoly in its goal to eliminate the need for refrigeration of vaccines and therapeutics.
